CVS Health Corp. stock gains analyst support as Overweight rating and higher targets reinforce recovery

CVS Health Corp. stock (ISIN US1266501006) is trading around USD 95.29 on the New York Stock Exchange as of September 11, 2026, while several major analyst houses reiterate positive views and raise price targets on the stock, signaling confidence in CVS Health’s earnings recovery and margin improvement.

Analysts reiterate positive ratings and raise price targets

On September 11, 2026, Cantor Fitzgerald reiterated an Overweight rating on CVS Health Corp. stock with a price target of USD 110.00, noting that the shares trade at USD 95.29 and have gained 28 percent over the past six months, reflecting strong momentum in the recovery story, according to Investing.com.

In the same analyst context, UBS raised its price target on CVS Health to USD 126.00, citing better-than-expected quarterly results and improving healthcare benefit margins as key drivers of the stock’s valuation rerating, as reported by Investing.com Korea.

Bernstein also increased its price target on CVS Health, lifting it from USD 106.00 to USD 112.00 and highlighting a faster-than-expected turnaround at the Aetna health insurance unit as a core driver of medium-term earnings growth, according to Investing.com Korea.

Consensus targets and valuation backdrop

Across the broader analyst community, CVS Health Corp. stock carries a consensus or average rating described as Moderate Buy or Overweight, with an average or consensus price target around USD 107.24, providing roughly 12 percent upside compared with a share price of about USD 95.31, per recent data from MarketBeat.

That same overview from MarketBeat notes that CVS Health’s full-year 2026 earnings guidance stands at USD 7.90 to USD 8.10 per share, which, at a share price in the mid-USD 90s, implies a forward price-to-earnings multiple around the low teens and positions the stock as a value-oriented health care name.

Another analyst commentary describes CVS Health’s valuation as about 13 times forward earnings, with recovery still underway after elevated healthcare costs in recent periods, particularly in Medicare-related business and litigation exposures, according to a sector comparison published by VT Markets.

Earnings guidance and margin recovery as key drivers

The 2026 earnings per share guidance range of USD 7.90 to USD 8.10, reaffirmed in recent communications and cited by MarketBeat, represents a significant step up from the earnings pressure experienced during earlier periods of higher healthcare benefit costs and Medicare reimbursement challenges.

Analysts such as UBS and Bernstein explicitly link their higher price targets to better-than-expected quarterly earnings and improving health benefit margins, indicating that CVS Health’s ability to manage medical cost trends and stabilize its insurance operations is central to the equity story, as detailed by Investing.com Korea.

The Stars quality rating framework referenced by Cantor Fitzgerald, which assesses Medicare plans’ performance, is another structural driver for CVS Health’s outlook; optimistic expectations for the 2027 Stars evaluation suggest potential upside for Aetna’s Medicare Advantage profitability if higher ratings translate into better reimbursement and enrollment trends, according to Investing.com Korea.

Risk factors: healthcare costs and regulatory exposure

Despite the constructive analyst stance, the recovery story for CVS Health Corp. stock comes with risk factors, including elevated Medicare and broader healthcare costs as well as litigation exposure related to programs such as 340B drug pricing, which several analysts flag as a focus area, according to Investing.com Korea.

A comparative valuation view places CVS Health alongside other diversified managed care and health service companies, noting that while recovery is underway, sensitivity to Medicare cost trends and litigation outcomes remains a central variable for future earnings trajectories, as highlighted in the sector table published by VT Markets.

Investor commentary from research houses such as Zacks suggests a more neutral stance, with CVS Health classified as a Hold and existing shareholders advised to maintain positions while prospective investors wait for a more favorable entry point, underscoring that, even with improving margins, the risk-reward profile is balanced at current valuations, according to Zacks.

Stock price level and recent performance

In recent trading, CVS Health Corp. stock closed at USD 95.38 on the New York Stock Exchange on September 10, 2026, marking a 0.3 percent gain for that session and trading between an intraday low and high in the mid-USD 90 range, according to a price summary from MarketWatch data cited by a corporate news overview.

By the evening of September 11, 2026, a German-language market update indicated that CVS Health shares were down 1.2 percent at USD 94.16 in New York trading, illustrating that the stock can fluctuate day to day even within a broadly upward six-month trend, according to finanzen.ch.

The combination of a recent six-month price gain of 28 percent, a current level around USD 95, and consensus price targets above USD 107 suggests that CVS Health Corp. stock has already priced in part of the earnings recovery but still offers potential upside if guidance for 2026 earnings per share in the USD 7.90 to USD 8.10 range is achieved or exceeded, as implied by the data discussed by MarketBeat and Investing.com.

More news and analyses on CVS Health Corp. stock